Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD).
Phase 1
Recruiting
- Conditions
- Inherited retinal dystrophiesMedDRA version: 20.0Level: PTClassification code: 10019899Term: Hereditary retinal dystrophy Class: 100000004850Therapeutic area: Diseases [C] - Eye Diseases [C11]
- Registration Number
- CTIS2022-501250-12-01
- Lead Sponsor
- Sparingvision
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method